Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214.

Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, Li X, Berry DL, Kallakury BV, Chauhan SC, Collins SP, Suy S, Kumar D.

PLoS One. 2013 Oct 22;8(10):e76994. doi: 10.1371/journal.pone.0076994. eCollection 2013.

2.

Circulatory miR-628-5p is downregulated in prostate cancer patients.

Srivastava A, Goldberger H, Dimtchev A, Marian C, Soldin O, Li X, Collins SP, Suy S, Kumar D.

Tumour Biol. 2014 May;35(5):4867-73. doi: 10.1007/s13277-014-1638-1. Epub 2014 Jan 30.

3.

The utility of urine-circulating miRNAs for detection of prostate cancer.

Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S.

Br J Cancer. 2016 Sep 6;115(6):707-15. doi: 10.1038/bjc.2016.233. Epub 2016 Aug 4.

4.

Detection of miRNAs in urine of prostate cancer patients.

Stuopelytė K, Daniūnaitė K, Jankevičius F, Jarmalaitė S.

Medicina (Kaunas). 2016;52(2):116-24. doi: 10.1016/j.medici.2016.02.007. Epub 2016 Mar 11.

5.

MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.

Xu Y, Qin S, An T, Tang Y, Huang Y, Zheng L.

Prostate. 2017 Jul;77(10):1167-1175. doi: 10.1002/pros.23376. Epub 2017 Jun 15.

PMID:
28617988
6.

Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis.

Foj L, Ferrer F, Serra M, Arévalo A, Gavagnach M, Giménez N, Filella X.

Prostate. 2017 May;77(6):573-583. doi: 10.1002/pros.23295. Epub 2016 Dec 19.

PMID:
27990656
7.

Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.

Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M.

Int J Cancer. 2015 Feb 15;136(4):875-9. doi: 10.1002/ijc.29054. Epub 2014 Jul 7.

8.

Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.

Koppers-Lalic D, Hackenberg M, de Menezes R, Misovic B, Wachalska M, Geldof A, Zini N, de Reijke T, Wurdinger T, Vis A, van Moorselaar J, Pegtel M, Bijnsdorp I.

Oncotarget. 2016 Apr 19;7(16):22566-78. doi: 10.18632/oncotarget.8124.

9.

Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.

Stephan C, Jung M, Rabenhorst S, Kilic E, Jung K.

Clin Chem Lab Med. 2015 Jun;53(7):1109-18. doi: 10.1515/cclm-2014-1000.

PMID:
25720086
10.

MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1.

Theodore SC, Davis M, Zhao F, Wang H, Chen D, Rhim J, Dean-Colomb W, Turner T, Ji W, Zeng G, Grizzle W, Yates C.

Oncotarget. 2014 Jun 15;5(11):3512-25.

11.

miRNAs as novel biomarkers in the management of prostate cancer.

Filella X, Foj L.

Clin Chem Lab Med. 2017 May 1;55(5):715-736. doi: 10.1515/cclm-2015-1073. Review.

12.

miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer.

Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, Ittmann M, Ozen M.

PLoS One. 2014 Jun 26;9(6):e98675. doi: 10.1371/journal.pone.0098675. eCollection 2014.

13.

Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.

Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, Chi KN.

Int J Mol Sci. 2013 Apr 10;14(4):7757-70. doi: 10.3390/ijms14047757.

14.

Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities.

Wang BD, Ceniccola K, Yang Q, Andrawis R, Patel V, Ji Y, Rhim J, Olender J, Popratiloff A, Latham P, Lai Y, Patierno SR, Lee NH.

Clin Cancer Res. 2015 Nov 1;21(21):4970-84. doi: 10.1158/1078-0432.CCR-14-1566. Epub 2015 Jun 18.

15.

Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker.

Erbes T, Hirschfeld M, Rücker G, Jaeger M, Boas J, Iborra S, Mayer S, Gitsch G, Stickeler E.

BMC Cancer. 2015 Mar 28;15:193. doi: 10.1186/s12885-015-1190-4.

16.

MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer.

Casanova-Salas I, Masiá E, Armiñán A, Calatrava A, Mancarella C, Rubio-Briones J, Scotlandi K, Vicent MJ, López-Guerrero JA.

PLoS One. 2015 May 13;10(5):e0125576. doi: 10.1371/journal.pone.0125576. eCollection 2015.

17.

MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.

Yang B, Liu Z, Ning H, Zhang K, Pan D, Ding K, Huang W, Kang XL, Wang Y, Chen X.

Cancer Biomark. 2016 Jul 8;17(2):223-30. doi: 10.3233/CBM-160634.

PMID:
27434290
18.

Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.

Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M, Ichikawa T, Seki N.

J Hum Genet. 2012 Nov 26;57(11):691-9. doi: 10.1038/jhg.2012.95. Epub 2012 Aug 2.

PMID:
22854542
19.

Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer.

Juzėnas S, Saltenienė V, Kupcinskas J, Link A, Kiudelis G, Jonaitis L, Jarmalaite S, Kupcinskas L, Malfertheiner P, Skieceviciene J.

PLoS One. 2015 Jul 14;10(7):e0132327. doi: 10.1371/journal.pone.0132327. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0135762.

20.

Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.

Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K.

Int J Cancer. 2010 Mar 1;126(5):1166-76. doi: 10.1002/ijc.24827.

Supplemental Content

Support Center